CN107028164A - A kind of liver protecting health food and preparation method thereof - Google Patents
A kind of liver protecting health food and preparation method thereof Download PDFInfo
- Publication number
- CN107028164A CN107028164A CN201610990989.4A CN201610990989A CN107028164A CN 107028164 A CN107028164 A CN 107028164A CN 201610990989 A CN201610990989 A CN 201610990989A CN 107028164 A CN107028164 A CN 107028164A
- Authority
- CN
- China
- Prior art keywords
- ginseng
- liver
- extract
- health food
- liver protecting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000004185 liver Anatomy 0.000 title claims abstract description 64
- 235000013402 health food Nutrition 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 239000000284 extract Substances 0.000 claims abstract description 67
- 241000208340 Araliaceae Species 0.000 claims abstract description 49
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 48
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 48
- 235000008434 ginseng Nutrition 0.000 claims abstract description 48
- 239000002994 raw material Substances 0.000 claims abstract description 22
- 235000008422 Schisandra chinensis Nutrition 0.000 claims abstract description 20
- 238000005469 granulation Methods 0.000 claims abstract description 11
- 230000003179 granulation Effects 0.000 claims abstract description 11
- 238000011049 filling Methods 0.000 claims abstract description 9
- 238000005498 polishing Methods 0.000 claims abstract description 9
- 241000736075 Schisandra Species 0.000 claims abstract 8
- 239000002775 capsule Substances 0.000 claims description 37
- 239000002245 particle Substances 0.000 claims description 32
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 23
- 239000000463 material Substances 0.000 claims description 19
- 239000000843 powder Substances 0.000 claims description 19
- 238000001035 drying Methods 0.000 claims description 17
- 235000020985 whole grains Nutrition 0.000 claims description 16
- 235000013305 food Nutrition 0.000 claims description 13
- 230000001954 sterilising effect Effects 0.000 claims description 10
- 239000000428 dust Substances 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 239000011122 softwood Substances 0.000 claims description 8
- 238000004659 sterilization and disinfection Methods 0.000 claims description 8
- 240000006509 Gynostemma pentaphyllum Species 0.000 claims description 7
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 244000000231 Sesamum indicum Species 0.000 claims description 3
- 235000003434 Sesamum indicum Nutrition 0.000 claims description 3
- 230000006378 damage Effects 0.000 abstract description 18
- 239000000126 substance Substances 0.000 abstract description 13
- 230000017531 blood circulation Effects 0.000 abstract description 4
- 239000012530 fluid Substances 0.000 abstract description 2
- 238000012545 processing Methods 0.000 abstract description 2
- 238000005728 strengthening Methods 0.000 abstract description 2
- 235000021393 food security Nutrition 0.000 abstract 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 33
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 25
- 231100000753 hepatic injury Toxicity 0.000 description 24
- 230000000694 effects Effects 0.000 description 23
- 240000006079 Schisandra chinensis Species 0.000 description 21
- 210000005229 liver cell Anatomy 0.000 description 21
- 230000002829 reductive effect Effects 0.000 description 21
- 206010067125 Liver injury Diseases 0.000 description 20
- 210000002966 serum Anatomy 0.000 description 19
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 238000011160 research Methods 0.000 description 17
- 229960003180 glutathione Drugs 0.000 description 16
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 14
- 108010082126 Alanine transaminase Proteins 0.000 description 14
- 238000012360 testing method Methods 0.000 description 13
- 229950005499 carbon tetrachloride Drugs 0.000 description 12
- 235000013399 edible fruits Nutrition 0.000 description 12
- 230000001681 protective effect Effects 0.000 description 12
- 241000700159 Rattus Species 0.000 description 11
- 230000006870 function Effects 0.000 description 10
- 240000008397 Ganoderma lucidum Species 0.000 description 9
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 239000013642 negative control Substances 0.000 description 9
- 230000001476 alcoholic effect Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 229930182494 ginsenoside Natural products 0.000 description 8
- 229940089161 ginsenoside Drugs 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 102000019197 Superoxide Dismutase Human genes 0.000 description 6
- 108010012715 Superoxide dismutase Proteins 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 230000004087 circulation Effects 0.000 description 6
- 239000000945 filler Substances 0.000 description 6
- 239000007902 hard capsule Substances 0.000 description 6
- 238000010348 incorporation Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 208000019425 cirrhosis of liver Diseases 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000003304 gavage Methods 0.000 description 5
- 230000002440 hepatic effect Effects 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 235000019640 taste Nutrition 0.000 description 5
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 4
- 108010024636 Glutathione Proteins 0.000 description 4
- 230000008485 antagonism Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 238000005660 chlorination reaction Methods 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 238000001784 detoxification Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 210000003494 hepatocyte Anatomy 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- FBFMBWCLBGQEBU-RXMALORBSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-2-[[(3s,5r,6s,8r,9r,10r,12r,13r,14r,17s)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2s)-6-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecah Chemical class O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FBFMBWCLBGQEBU-RXMALORBSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 208000004930 Fatty Liver Diseases 0.000 description 3
- 206010019708 Hepatic steatosis Diseases 0.000 description 3
- 241001165494 Rhodiola Species 0.000 description 3
- 108090000340 Transaminases Proteins 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- -1 carbon tetrachloride Propylhomoserin Chemical compound 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 231100000012 chronic liver injury Toxicity 0.000 description 3
- 238000013329 compounding Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 208000010706 fatty liver disease Diseases 0.000 description 3
- 229930187479 gypenoside Natural products 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 230000003859 lipid peroxidation Effects 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- 244000283207 Indigofera tinctoria Species 0.000 description 2
- 208000005374 Poisoning Diseases 0.000 description 2
- 244000042430 Rhodiola rosea Species 0.000 description 2
- 235000003713 Rhodiola rosea Nutrition 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 210000003712 lysosome Anatomy 0.000 description 2
- 230000001868 lysosomic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- YUKQRDCYNOVPGJ-UHFFFAOYSA-N thioacetamide Chemical compound CC(N)=S YUKQRDCYNOVPGJ-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 102000014898 transaminase activity proteins Human genes 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 241000432824 Asparagus densiflorus Species 0.000 description 1
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 102000002734 Collagen Type VI Human genes 0.000 description 1
- 108010043741 Collagen Type VI Proteins 0.000 description 1
- 241000220284 Crassulaceae Species 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000222336 Ganoderma Species 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 206010019837 Hepatocellular injury Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- GGLZPLKKBSSKCX-YFKPBYRVSA-N L-ethionine Chemical compound CCSCC[C@H](N)C(O)=O GGLZPLKKBSSKCX-YFKPBYRVSA-N 0.000 description 1
- 241000218377 Magnoliaceae Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000222341 Polyporaceae Species 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000003995 blood forming stem cell Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 231100000359 cholestasis Toxicity 0.000 description 1
- 230000007870 cholestasis Effects 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- MOVRKLZUVNCBIP-RFZYENFJSA-N cortancyl Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O MOVRKLZUVNCBIP-RFZYENFJSA-N 0.000 description 1
- XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000437 hepatocellular injury Toxicity 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000001853 liver microsome Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- PWZUUYSISTUNDW-VAFBSOEGSA-N quinestrol Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@]4(O)C#C)C)CC2=CC=3OC1CCCC1 PWZUUYSISTUNDW-VAFBSOEGSA-N 0.000 description 1
- 229960001424 quinestrol Drugs 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 238000005464 sample preparation method Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 229930192961 schisandrol Natural products 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000004895 subcellular structure Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/424—Gynostemma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of liver protecting health food, by raw material ginseng 130 220 by weight, Ganodenna Lucidum P.E 10 100, Herb Gynostemmae Pentaphylli extract 10 100, gadol extract 10 100, Schisandra chinens P.E 10 100, it is made through dispensing, granulation, filling, polishing step.The present invention is from ginseng, the Ganodenna Lucidum P.E strengthened the body resistance to consolidate the constitution; it is equipped with gadol extract, the Herb Gynostemmae Pentaphylli extract of qi and activate blood circulation; help and formed using the Schisandra chinens P.E of nourishing generate fluid as Raw material processing again; by strengthening the body resistance to consolidate the constitution, qi and activate blood circulation and reach there is the purpose of auxiliary protection to chemical damage, food security of the present invention is effective.The invention also discloses a kind of preparation method of liver protecting health food.
Description
Technical field
The invention belongs to technical field of health care food, and in particular to a kind of liver protecting health food and preparation method thereof.
Background technology
Liver be maintain human metabolism important organ, to biosynthesis, bioconversion, removing toxic substances, secretion, excretion,
Immune each side is played an important role, with economic development, and people's living standard is improved, the change of live and work mode, wine
Essence, medicine, environmental pollution and the excessive intake of fuel value of food cause the potential hazard to the chemical damage of liver more next
More serious, such as fatty liver, the alcoholic liver incidence of disease have trend that is soaring and having rejuvenation year by year.Effective liver protecting is protected
Health food is increasingly valued by people and welcome.
The content of the invention
It is an object of the invention to provide a kind of liver protecting health food, especially there is protection to make chemical damage
With.
Present invention also offers a kind of preparation method of liver protecting health food.
The present invention is adopted the following technical scheme that：
A kind of liver protecting health food, includes ginseng, Ganodenna Lucidum P.E, Herb Gynostemmae Pentaphylli extract, gadol extract, the five tastes
Seed extract.
A kind of liver protecting health food, is made up of raw material through dispensing, granulation, filling, polishing step, wherein raw material press with
Lower weight：
Ginseng 130-220 Ganodenna Lucidum P.E 10-100 Herb Gynostemmae Pentaphylli extracts 10-100
Gadol extract 10-100 Schisandra chinens P.Es 10-100.
Further, the raw material is preferentially matched by following parts by weight：
Ginseng 150-210 Ganodenna Lucidum P.E 20-80 Herb Gynostemmae Pentaphylli extracts 20-80
Gadol extract 20-80 Schisandra chinens P.Es 20-80.
Further, the raw material is preferentially matched by following parts by weight：
Ginseng 170-210 Ganodenna Lucidum P.E 30-60 Herb Gynostemmae Pentaphylli extracts 30-60
Gadol extract 30-60 Schisandra chinens P.Es 20-50.
Further, the raw material is preferentially matched by following parts by weight：
The Herb Gynostemmae Pentaphylli extract 50 of 180 Ganodenna Lucidum P.E of ginseng 50
The Schisandra chinens P.E 30 of gadol extract 40.
Further, the food is capsule form.
In above-mentioned raw materials, the ginseng is commercially available low residual sun-dried ginseng, the Ganodenna Lucidum P.E, Herb Gynostemmae Pentaphylli extract, red scape
Its extract, Schisandra chinens P.E are that the enterprise for producing qualification with extract produces commercially available prod.
A kind of a kind of preparation method of liver protecting health food as described above, comprises the following steps：
1. dispensing：Weight point weighs raw material, and ginseng crushed after being dried crosses 100 mesh sieves formation ginseng fine powder, and sterilizing is standby；By spirit
It is well mixed again with ginseng fine powder after sesame extract, Herb Gynostemmae Pentaphylli extract, gadol extract, Schisandra chinens P.E mixing；
2. pelletize：With 70-90% ethanol softwoods, above-mentioned dispensing into mixed material the granulation of 16 mesh is made, in 55-60 DEG C of drying,
Cross 14 mesh sieve whole grains；
3. fill：Particle after above-mentioned whole grain is loaded into No. 0 capsule, 18-25 DEG C of environment temperature, relative humidity 45%-60% is controlled；
4. polish：Populated capsule is put into capsule polisher, the dust in capsule surface is removed, surface smoothness is improved.
Further, in the batching step, ginseng is in 50-70 DEG C of crushed after being dried；Ginseng fine powder 5kGy dosage60Co irradiation sterilizations.
In above-mentioned raw materials, ginseng is the drying root and rhizome of Araliaceae ginseng.Sweet, slight bitter, puts down.Returns spleen, lung, the heart
Through.Ginseng is one of China's special product valuable ingredient of traditional Chinese medicine, in ancient medicine books first appeared in《Sheng Nong's herbal classic》" tonifying five zang organs, peace essence
God, determines soul, stop palpitate with fear ", it is classified as top grade.Ginseng main chemical compositions have ginsenoside, carbohydrate, amino acids and peptides,
Vitamins etc., can reinforce vital energy, and veins takes off admittedly reinforces the spleen to benefit the lung, and promotes the production of body fluid, and calms the nerves, be clinically used for it is physically weak to be taken off, spleen eating less,
The diseases such as insomnia of palpitating with fear.Modern pharmacological research shows that ginseng has anti-liver injury effect.Ginseng can increase the various enzymatic activitys of liver,
Strengthen liver detoxification power, have obvious removing toxic substances and protective effect to the liver of alcoholism.Ginsenoside can be by cell
The suppression of the enzyme of pigment P -450, and the mitochondrial lipid peroxidation of rat hepatocytes caused by protecting carbon tetrachloride.The total soap of ginseng
Glycosides can significantly reduce the level of lipid for the poisoning liver cell caused by carbon tetrachloride, suppress liver cell lipid peroxidation,
And glutamic-pyruvic transaminase and glutamic-oxalacetic transaminease level are reduced, protect lipid film.General ginsenoside remarkably promote poisoning liver cell RNA and
DNA synthesis.Ultrastructural observation confirms that general ginsenoside can mitigate carbon tetrachloride to liver cell chromatin, mitochondria, endoplasm
The infringement of net and ribosome, is as a result pointed out, and general ginsenoside has the effect of anti-carbon tetrachloride-injured rat hepatocytes.Research
Ginsenoside to carbon tetrachloride cause rat chronic hepatic injury influence when find, ginsenoside low dose can reduce serum transaminase
Aspartate transaminase, alanine aminotransferase levels, increase the content of serum superoxide dismutases, reduce mda content,
Illustrate that ginsenoside causes chronic liver injury to have protective effect in carbon tetrachloride.The research such as Gao Shuxian shows ginseng extract to four
Acute liver damage caused by chlorination carbon, thioacetamide, prednisone acetate has effective preventive and therapeutic action, can substantially reduce
Glutamic-pyruvic transaminase, and heavy dose of smaller dose administration group effect becomes apparent from.Ginseng pharmacopeia recommended amounts are 3~9g/ days, this product consumption
For 1.08g/ days.
Ganodenna Lucidum P.E extracted forms for the drying fructification of On Polyporaceae red sesame.Sweet, slight bitter, it is mild-natured.Tool
Strengthen the body resistance to consolidate the constitution, effect of strengthening by means of tonics.Ganoderma lucidum contains polysaccharide, triterpenes, nucleosides, sterol, alkaloid, amino acid, micro member
There is a variety of chemical composition such as element antitumor, liver protection, regulation to be immunized, anti-ageing bioactivity of waiting for a long time.GL-B is to the different sulphur of α-naphthalene
The influence of Liver Damage in Rats caused by cyanate is shown：GL-B can reduce acute jaundice model（Experimental cholestasis model）
Rat blood serum bilirubin, transaminase, the effect with improvement liver organization damage.Open the research such as strong and show that ganoderma lucidum is to four chlorinations
Serum glutamic pyruvic transminase rise and the accumulation of triglycerides have obvious reduction to act on caused by carbon, and can mitigate ethionine
Caused fatty liver, promotes liver cell regeneration, strengthens the function of detoxification of liver.Reality of the GL-B to preventing alcoholic liver injury
Test research to find, the glutathione of GL-B group mouse, glutathione peroxidase and superoxide dismutase contain
Amount is above hepatic injury control group, and the content of MDA, triglycerides is below hepatic injury control group, points out GL-B tool
There is certain prevention Ethanol hepatic injury.He Xuebin etc. shows the liver-protective experimental study of GL-B, ganoderma lucidum
Polysaccharide has significant protective effect to the Histological injury of carbon tetrachloride induced mice, to caused by cell and cell membrane damage
Serum alanine aminotransferase rise has obvious antagonism.Clinical research finds that ganoderma lucidum, which has, preferably reduces fat
The elevated effect of hepatopath's serum glutamic pyruvic transminase, while also there is certain curative effect to fatty liver.He Hui etc., which is studied, to be shown, ganoderma lucidum
Peptide can significantly reduce glutamic-pyruvic transaminase caused by Alcoholic Hepatic Injury, glutamic-oxalacetic transaminease activity and MDA, glycerine three
The drop of the rise of ester content, the effectively activity and reductive glutathione content of antagonism superoxide dismutase from liver.Grind
Study carefully and show, ganoderma lucidum mycelium can make the elevated Serum alanine amino transaminases of chemical damage mouse, AST and liver index
Reduction, and mitigate the damaging change of hepatic pathology.Xu Li etc. by experimental studies have found that, ganoderma tea have to mouse it is antifatigue,
Anti anoxia and the effect for increasing liver rna content.The pharmacopeia recommended amounts of ganoderma lucidum 6~12g/ days, Ganodenna Lucidum P.E withdrawal ratio is
20:1, crude drug amount is converted to for 1000g, and this product consumption is 6.0g/ days.
Herb Gynostemmae Pentaphylli extract forms for cucurbitaceous plant gynostemma pentaphylla dry aerial parts are extracted.Slight bitter, it is cold in nature；Return lung
Through.Stock indigo plant mainly contains saponins, carbohydrate, flavonoids, sterols, various amino acid and trace element etc..Research is found, is twisted
Stock indigo plant can prevent necrosis of liver cells by anti-oxidant, stabilizing cell membrane and lysosome membrane and reach and cause hepatic injury to carbon tetrachloride
Protective effect.The research such as Hu Baochun finds that gynostemma pentaphylla can mitigate murine liver tissue caused by carbon tetrachloride and damage, and improve liver
The function of albumin is synthesized, mitigates serum alanine aminotransferase activity, while being found through zoopery, gynostemma pentaphylla can prevent tetrachloro
Change infringement of the carbon to liver cell DNA, protect its liver cell DNA to synthesize, and reduce the effusion of liver cell alanine transaminase, to liver
Cell has significant protective effect.Separately there are studies have shown that gypenosides to damage big white mouse Acute Hepatic caused by carbon tetrachloride
Hinder tool to improve significantly, biochemical and pathological index can be made to take a turn for the better, also with liver detoxification function, had to liver cell regeneration
Certain facilitation.Wei Dengming etc. research find, Gypenosides prevent and treat liver fibrosis when, can by removing free radical,
Lipoid peroxidization resistant, and reach Liver protection function.Ten thousand beautiful wait study discovery, and Gypenosides can significantly reduce liver fibrosis
Hyaluronic acid, III Collagen Type VI and Laminin ELISA in glutamic-pyruvic transaminase, total bilirubin, total bile acid level and serum in rat blood serum
Level, and the collagenous fibres generation caused by albumin attack can be reduced, improve rat liver fibrosis pathology damage, illustrate gynostemma pentaphylla
Total glycosides has the effect of protection Liver Function.Gynostemma pentaphylla（《Guangxi Chinese medicine standard》Second）Recommended amounts are 6~10g/ days,
Herb Gynostemmae Pentaphylli extract withdrawal ratio is 8:1, crude drug amount is converted to for 400g, and this product consumption is 2.4g/ days.
Gadol extract extracted forms for the drying root and rhizome of crassulaceae plants rhodiola.Property is sweet, bitter,
It is flat, return lung, the heart channel of Hang-Shaoyin, the function with qi and activate blood circulation, promotes blood circulation and relievings asthma, for qi deficiency to blood stasis, chest impediment and cardialgia, hemiplegia, burnout
Asthma.The main component of rhodiola root has rhodioside, Radix Phodiolae Polyose etc..Pharmaceutical research finds that gadol extract can be bright
Mda content in aobvious reduction acute hepatic injury mice serum alanine aminotransferase, aspartate transaminase and liver tissue homogenate,
The activity of superoxide dismutase is improved, points out gadol extract to can obviously improve the pathologic of acute hepatic injury mice liver
Damage.The research such as Rong Li finds that rhodioside intervention processing can be improved rat blood serum liver function indexes, it is possible to decrease hepatic tissue
Mda content, rise superoxide dismutase activity, mitigate liver histopathology change, have protective effect to hepatic injury.Separately
There is studies have shown that gadol extract to reduce the alanine transaminase in Paracetamol induced Acute hepatic injury mice serum
With the content of aspartate transaminase, there is certain protective effect to acute liver damage.Chen Xiujin etc. is to ganoderma lucidum rhodiola rosea compound
The research of capsule finds that ganoderma lucidum rhodiola rosea compound capsule can reduce alanine transaminase and asparagus fern in serum caused by carbon tetrachloride
Propylhomoserin shifts the rise of enzyme level, points out it to have protective effect to chemical damage.Chen Yanjun etc. experimental studies have found that, red scape
It can suppress the formation and development of the Experimental Liver Fibrosis of tetrachloro-methane induction, and its mechanism is increased by suppressing HSCs
Grow, reduce the secretion of liver cell epimatrix, promote collagenous fibres degraded two to finally play the effect of preventing and treating liver fibrosis.Rhodiola root
Pharmacopeia recommended amounts 3~6g/ days, gadol extract withdrawal ratio is 10:1, crude drug amount is converted to for 400g, and this product consumption is
2.4g/ day.
Schisandra chinens P.E extracted forms for the dry mature fruit of magnoliaceae schisandra.It is sour, it is sweet, it is warm-natured.
Return lung, the heart channel of Hang-Shaoyin.With astringent or styptic treatment for spontaneous sweating, the effect of nourishing generate fluid of convergence.The fruit of Chinese magnoliavine contains volatile oil, organic acid, vitamin, lignin, three
A variety of chemical compositions such as terpene and polysaccharide.Modern pharmacological research finds that schisandrol extract can be reduced caused by chemical substance
Serum transaminase rise is acted on, can obvious inducing mouse and rat liver microsomes cytochrome P-450 activity, the solution of enhancing liver
Malicious function, moreover it is possible to improve resistivity of the body to oxygen free radical injury, and the biological conjunction of hepatic protein and glycogen can be promoted
Into the prompting fruit of Chinese magnoliavine has good protective effect to chemical damage.The research such as Zhang Minghua shows that the fruit of Chinese magnoliavine is to four chlorinations
Serum glutamic pyruvic transminase rise caused by the hepatic injury that carbon, thioacetamide and second quinestrol are caused has reduction to make
With while can also make the high serum glutamic pyruvic transminase of hepatitis reduces.The liver cell histochemistry of animal shows that the fruit of Chinese magnoliavine can
Mitigate the chemical substance dysbolism of toxic hepatitis damage, slightly increase hepatic glycogen, mitigate hepatic cell fattydegeneration, in mitigation
Pathogenic destruction of the factor to stem cell mitochondria and lysosome of poison.The research such as Xu Keyu finds that Chinese magnoliavine fruit polysaccharide extract is to liver
Cell has significant protective effect, and this effect may be with lipid peroxidation pair caused by its antagonism CCl4 toxic metabolites
The damage of liver subcellular structure is relevant.It is another there are some researches show, the fruit of Chinese magnoliavine and its benevolence ethanol extract to carbon tetrachloride caused rabbit,
Rat and mouse liver injury cause glutamic-pyruvic transaminase rise to have obvious reduction to act on, while also can be third turn of the high paddy of hepatitis
Ammonia enzyme is reduced, moreover it is possible to mitigate the metabolism obstacle of toxic liver injury, promotes the effect of liver cell internal protein.Pharmacopeia is recommended
Amount 2~6g/ days, Schisandra chinens P.E withdrawal ratio is 10:1, crude drug amount is converted to for 300g, and this product consumption is 1.8g/ days.
Prior art has no that ginseng, Ganodenna Lucidum P.E, Herb Gynostemmae Pentaphylli extract, gadol extract, the fruit of Chinese magnoliavine are extracted so far
The public technology of thing compounding, also without disclosed by ginseng, Ganodenna Lucidum P.E, Herb Gynostemmae Pentaphylli extract, gadol extract, the fruit of Chinese magnoliavine
The specific formulation of extract compounding.The ginseng of the present invention, Ganodenna Lucidum P.E, Herb Gynostemmae Pentaphylli extract, gadol extract, the fruit of Chinese magnoliavine
Extract compounding can significantly reduce glutamic-pyruvic transaminase caused by Alcoholic Hepatic Injury, glutamic-oxalacetic transaminease activity and the third two
The rise of aldehyde, content of triglyceride, effectively antagonism superoxide dismutase from liver activity contain with reductive glutathione
The decline of amount.Rat blood serum transaminase aspartate transaminase, alanine aminotransferase levels can also be reduced, increase serum super oxygen
The content of thing mutase, reduces mda content, illustrates to cause chronic liver injury to have protective effect in carbon tetrachloride.And to four
Big white mouse acute liver damage tool is improved significantly caused by chlorination carbon, and biochemical and pathological index can be made to take a turn for the better, also had
Liver detoxification function, there is certain facilitation to liver cell regeneration.Fully show that ginseng, Ganodenna Lucidum P.E, gynostemma pentaphylla are extracted
Thing, gadol extract, Schisandra chinens P.E compound have the protective effect effect of more preferable chemical damage.
Food of the present invention has auxiliary protection function test report to chemical damage
1. material and method
1.1 samples and compound method
Food of the present invention is brown yellow granule and powder.
Sample preparation method：Tested material food capsule content 3.5g, 7.0g, 10.5g of the present invention is weighed respectively with right amount
Distillation is water-soluble to 200 ml（The ml of capacity 200 is prepared every time）, basic, normal, high three dosage group compound concentrations are respectively：0.0175
Fully mixed before g/ml, 0.035 g/ml, 0.0525 g/ml, gavage.
1.2 detection kit
MDA（MDA）Determine kit, lot number 20130321；Reduced glutathione（GSH）Determine kit, lot number
20130325。
1.3 experimental animal
SPExe Kunming kind female mice, body weight 18-22 g, totally 50.There is provided by Hubei Province Animal Experimental Study center, experiment
Animal productiong licensing number is（Hubei Province）2008-0005, experimental animal is in be using licensing（Hubei Province）2012-0065. Laboratory Temperature
20-26 DEG C of degree, humidity 40-70%.
1.4 experiment packets and dose design
Animal is randomly divided into 5 test groups.Human body recommends daily intaking amount to be that 2.1g/60kgBW is 0.035 g/ kgBW, respectively
Expand 10,20,30 times（0.035 g/ kgBW、0.70 g/ kgBW、1.05 g/ kgBW）It is used as basic, normal, high three dosage
Group, separately sets negative control group and liver injury model control group, every group of 10 mouse.
1.5 experimental method
The tested material of the daily oral gavage respective concentration of each dosage group, mouse stomach capacity is 0.2ml/10gBW, negative control
Group and liver injury model control group give equivalent distilled water.Animal is weighed weekly twice, and tested material gavage is adjusted by changes of weight
Amount, experiment gavage of the 30th day model group and each dosage gives the ml/10kgBW of 50% ethanol 14, and negative control group, which is given, waits appearance
The distilled water of amount.Animal is weighed weekly twice, and tested material gavage amount is adjusted by changes of weight, tests the 30th day model group and each dose
Gavage of amount group gives the ml/10gBW of 50% ethanol 14, and the distilled water for the capacity such as negative control group is given, fasting claims for 16 hours
Cervical dislocation puts to death animal after weight.Liver, which is weighed, calculates dirty/body ratio, takes 0.5g livers to prepare and every guidance is carried out after liver homogenate
Mark the detection and liver pathomorphology inspection of (MDA, reduced form GSH, TG).MDA, reduced form GSH detection methods and calculating side
Method builds up the kit explanation of Bioengineering Research Institute with reference to Nanjing, and 7020 types that TG is produced using Hitachi, Ltd are automatically given birth to
Change analyzer detection.
1.6 statistical method
Result of the test is with EXCELvfuuovt according to storehouse, and statistical analysis software is SPSS1.5, using variance analysis and nonparametric statistics
Method（Rank test）.Homogeneity test of variance is first carried out, variance is neat, with mean between multiple experimental groups and a control group two-by-two
Knot is counted compared with method；Data to abnormal or heterogeneity of variance carry out appropriate variable conversion, normal state or variance to be met
After neat requirement, carry out counting still not up to positive after the conversion of adk variables with the data after conversion and remember or the neat purpose of variance, use order instead
Counted with examining.
2nd, Testing index
2.1 body weight
MDA, TG, reduced form GSH in 2.2 liver homogenates
2.3 liver pathomorphology inspections
2.3.1 pathological observation material
Each group animal's liver is done into cross section materials, frozen section, oil red dyeing in the middle part of liver or so.Under an optical microscope
Observe hepatocellular injury degree.
2.3.2 pathological diagnosis standard：
2.3.2.1 evaluation method
Microscopy, from the pathological change of one end visual field start recording cell of liver, with 40 times of object lens Continuous Observations, entirely tissue is cut
Piece.Main detection fat drips are in the distribution of liver, scope and area.
2.3.2.2 standards of grading
The area in the visual field shared by the various lesions in each visual field is recorded respectively, the lesion total score in the visual field observed by adding up.
Fat drips are dispersed in liver cell, rare 0 point
Liver cell containing fat drips is no more than 1/4 1 points
Liver cell containing fat drips is no more than 1/2 2 points
Liver cell containing fat drips is no more than 3/4 3 points
Hepatic tissue almost substitutes 4 points by fat drips
2.3.2.3 result judgement
Meet either condition, can determine that given the test agent have have auxiliary protection function to alcoholic liver injury.
2.3.2.3.1 liver MDA, tri- Testing index results of reduced form GSH and TG are positive.
2.3.2.3.2 wantonly two indexs are positive in liver MDA, tri- indexs of reduced form GSH and TG and Histopathology is examined
The fruit that comes to an end is positive.
3. result of the test
Influence of 3.1 food of the present invention to mouse weight
As seen from Table 1, tested material has no significant effect to the body weight before and after each dosage group mouse test；Compared with negative control group,
There are no significant for difference（P ＞ 0.05）.
Influence of the food of the present invention of table 1 to mouse weight（X ± SD, n=10）
Influence of 3.2 food of the present invention to MDA, reduced form GSH and TG in mouse liver even slurry
Give after the alcohol of mouse 50%, compared with negative control group by 14 ml/10kgBW dosage, liver injury model control group liver
The rise of MDA values, the reduction of reduced form GSH values result in homogenate, TG values result rise, difference have conspicuousness（P ＜ 0.01）, explanation
This experimental model is set up.Compared with liver injury model control group, MDA values are reduced in middle and high dosage group liver homogenate, and difference has aobvious
Work property（P ＜ 0.05）；Middle dose group can reduce TG values in liver homogenate, and difference has conspicuousness（P ＜ 0.05）.Can be determined that MDA and
Three index results of reduced form type GSH, TG value are the positive.（Table 2）
MDA, reduced form GSH, TG measured value in each group mouse liver even slurry of table 2（X ± SD, n=10）
Note：Each dosage group is compared with model control group, * P ＜ 0.05***P ＜ 0.01；Model group is compared with negative control group, #P
〈0.05##P〈0.01。
Influence of 3.3 food of the present invention to mouse liver Histopathology
As seen from Table 3, model control group is compared with negative control group, and the scoring of liver fat cell degeneration, which statistically has, extremely to be shown
Write sex differernce（P〈0.01）, it has been successfully, reproduced out experiment mice alcoholic liver injury model.Compared with model group, high dose group liver
Cell degeneration program mitigates, and statistically has significant difference（P〈0.05）, Histopathology index can determine whether as the positive.
Influence of the food of the present invention of table 3 to mouse liver Histopathology（X ± SD, n=10）
Note：Compared with model control group, * P ＜ 0.05, * * P ＜ 0.01.
4. conclusion
（1）Body weight and model control group are poor different without conspicuousness before and after each Dose Groups Study；With negative control group comparing difference
Also without conspicuousness；
（2）Satisfactory alcoholic liver injury model is established, is compared with liver injury model control group：Middle and high dose of tested material
Amount group liver homogenate MDA values are reduced, and tested material high dose group liver homogenate reduced form GSH values rise, difference has conspicuousness EPC to try in thing
Dosage group can reduce TG values in liver homogenate, there is significant difference.It can be determined that three index knots of MDA and reduced form GSH, TG value
Fruit is the positive.
（3）Liver pathology inspection result is shown：Tested material high dose group hepar damnification degree is lighter than liver injury model pair
According to group, hepatic cell fattydegeneration program mitigates, and model control group is poor different has conspicuousness.
This results of animal shows：MDA, three indexs of reduced form GSH, TG value and pathology in given the test agent liver homogenate
Histological indications are the positive, foundation《Health food is examined and assessment technique specification》Middle criterion, judges that this is tested
Sample has auxiliary protection function to Alcoholic Hepatic Injury.
Embodiment
With reference to embodiment, the present invention is described in more detail.But skilled in the art realises that, following embodiments
It is not limiting the scope of the invention, any improvement and change made on the basis of the present invention, all guarantor in the present invention
Within the scope of shield.
Embodiment 1
Step one：Dispensing
Following raw material is weighed by weight：Ginseng is dried（60℃）After crush, cross 100 mesh sieves 180 parts of ginseng fine powder, be used in combination
5kGy dosage60It is standby after Co irradiation sterilizations；By 50 parts of Ganodenna Lucidum P.E, 50 parts of Herb Gynostemmae Pentaphylli extract, gadol extract 40
Mixed again with ginseng fine powder after part, 30 parts of mixing of Schisandra chinens P.E, incorporation time 20 minutes makes its uniform.
Step 2：Granulation
With 85% ethanol softwood, 16 mesh particles are made through laboratory oscillating granulator in the mixed material mixed, will be made
The homogeneous particle of size be placed in hot air circulation drying oven, be dried, dried particle is crossed 14 by 55 DEG C of drying temperature
Mesh sieve carries out whole grain so that all homogeneous sizes of particle.
Step 3：Filling
The particle after whole grain is loaded into No. 0 capsule with automatic hard capsule filler, 18-25 DEG C of environment temperature is controlled, it is relatively wet
Spend 45%-60%.
Step 4：Polishing
Populated capsule is put into capsule polisher, the dust in capsule surface is removed, surface smoothness is improved.
Embodiment 2
Step one：Dispensing
Following raw material is weighed by weight：Dry（55℃）After crush, cross 220 parts of the ginseng fine powder of 100 mesh sieves, and use 5kGy agent
Amount60It is standby after Co irradiation sterilizations；By 100 parts of Ganodenna Lucidum P.E, 100 parts of Herb Gynostemmae Pentaphylli extract, 100 parts of gadol extract,
Mixed again with ginseng fine powder after 100 parts of mixing of Schisandra chinens P.E, incorporation time 25 minutes.
Step 2：Granulation
With 80% ethanol softwood, 16 mesh particles are made through laboratory oscillating granulator in the mixed material mixed, will be made
The homogeneous particle of size be placed in hot air circulation drying oven, be dried, dried particle is crossed 14 by 58 DEG C of drying temperature
Mesh sieve carries out whole grain so that all homogeneous sizes of particle.
Step 3：Filling
The particle after whole grain is loaded into No. 0 capsule with automatic hard capsule filler, 18-25 DEG C of environment temperature is controlled, it is relatively wet
Spend 45%-60%.
Step 4：Polishing
Populated capsule is put into capsule polisher, the dust in capsule surface is removed, surface smoothness is improved.
Embodiment 3
Step one：Dispensing
Following raw material is weighed by weight：Dry（60℃）After crush, cross 210 parts of the ginseng fine powder of 100 mesh sieves, and use 5kGy agent
Amount60It is standby after Co irradiation sterilizations；By 80 parts of Ganodenna Lucidum P.E, 80 parts of Herb Gynostemmae Pentaphylli extract, 80 parts of gadol extract, five
Mixed again with ginseng fine powder after the 80 parts of mixing of taste seed extract, incorporation time 15 minutes.
Step 2：Granulation
With 70% ethanol softwood, 16 mesh particles are made through laboratory oscillating granulator in the mixed material mixed, will be made
The homogeneous particle of size be placed in hot air circulation drying oven, be dried, dried particle is crossed 14 by 60 DEG C of drying temperature
Mesh sieve carries out whole grain so that all homogeneous sizes of particle.
Step 3：Filling
The particle after whole grain is loaded into No. 0 capsule with automatic hard capsule filler, 18-25 DEG C of environment temperature is controlled, it is relatively wet
Spend 45%-60%.
Step 4：Polishing
Populated capsule is put into capsule polisher, the dust in capsule surface is removed, surface smoothness is improved.
Embodiment 4
Step one：Dispensing
Following raw material is weighed by weight：Dry（68℃）After crush, cross 170 parts of the ginseng fine powder of 100 mesh sieves, and use 5kGy agent
Amount60It is standby after Co irradiation sterilizations；By 60 parts of Ganodenna Lucidum P.E, 60 parts of Herb Gynostemmae Pentaphylli extract, 60 parts of gadol extract, five
Mixed again with ginseng fine powder after the 50 parts of mixing of taste seed extract, incorporation time 24 minutes.
Step 2：Granulation
With 85% ethanol softwood, 16 mesh particles are made through laboratory oscillating granulator in the mixed material mixed, will be made
The homogeneous particle of size be placed in hot air circulation drying oven, be dried, dried particle is crossed 14 by 57 DEG C of drying temperature
Mesh sieve carries out whole grain so that all homogeneous sizes of particle.
Step 3：Filling
The particle after whole grain is loaded into No. 0 capsule with automatic hard capsule filler, 18-25 DEG C of environment temperature is controlled, it is relatively wet
Spend 45%-60%.
Step 4：Polishing
Populated capsule is put into capsule polisher, the dust in capsule surface is removed, surface smoothness is improved.
Embodiment 5
Step one：Dispensing
Following raw material is weighed by weight：Dry（65℃）After crush, cross 170 parts of the ginseng fine powder of 100 mesh sieves, and use 5kGy agent
Amount60It is standby after Co irradiation sterilizations；By 40 parts of Ganodenna Lucidum P.E, 40 parts of Herb Gynostemmae Pentaphylli extract, 30 parts of gadol extract, five
Mixed again with ginseng fine powder after the 20 parts of mixing of taste seed extract, incorporation time 30 minutes.
Step 2：Granulation
With 75% ethanol softwood, 16 mesh particles are made through laboratory oscillating granulator in the mixed material mixed, will be made
The homogeneous particle of size be placed in hot air circulation drying oven, be dried, dried particle is crossed 14 by 60 DEG C of drying temperature
Mesh sieve carries out whole grain so that all homogeneous sizes of particle.
Step 3：Filling
The particle after whole grain is loaded into No. 0 capsule with automatic hard capsule filler, 18-25 DEG C of environment temperature is controlled, it is relatively wet
Spend 45%-60%.
Step 4：Polishing
Populated capsule is put into capsule polisher, the dust in capsule surface is removed, surface smoothness is improved.
Embodiment 6
Step one：Dispensing
Following raw material is weighed by weight：Dry（50℃）After crush, cross 130 parts of the ginseng fine powder of 100 mesh sieves, and use 5kGy agent
Amount60It is standby after Co irradiation sterilizations；By 30 parts of Ganodenna Lucidum P.E, 30 parts of Herb Gynostemmae Pentaphylli extract, 30 parts of gadol extract, five
Mixed again with ginseng fine powder after the 20 parts of mixing of taste seed extract, incorporation time 30 minutes.
Step 2：Granulation
With 85% ethanol softwood, 16 mesh particles are made through laboratory oscillating granulator in the mixed material mixed, will be made
The homogeneous particle of size be placed in hot air circulation drying oven, be dried, dried particle is crossed 14 by 55 DEG C of drying temperature
Mesh sieve carries out whole grain so that all homogeneous sizes of particle.
Step 3：Filling
The particle after whole grain is loaded into No. 0 capsule with automatic hard capsule filler, 18-25 DEG C of environment temperature is controlled, it is relatively wet
Spend 45%-60%.
Step 4：Polishing
Populated capsule is put into capsule polisher, the dust in capsule surface is removed, surface smoothness is improved.
Claims (8)
1. a kind of liver protecting health food, it is characterised in that the food includes ginseng, Ganodenna Lucidum P.E, gynostemma pentaphylla and carried
Take thing, gadol extract, Schisandra chinens P.E.
2. a kind of liver protecting health food, is made up of raw material through dispensing, granulation, filling, polishing step, wherein raw material is by following
Weight：
Ginseng 130-220 Ganodenna Lucidum P.E 10-100 Herb Gynostemmae Pentaphylli extracts 10-100
Gadol extract 10-100 Schisandra chinens P.Es 10-100.
3. a kind of liver protecting health food according to claim 2, it is characterised in that the raw material presses following parts by weight
Proportioning：
Ginseng 150-210 Ganodenna Lucidum P.E 20-80 Herb Gynostemmae Pentaphylli extracts 20-80
Gadol extract 20-80 Schisandra chinens P.Es 20-80.
4. a kind of liver protecting health food according to claim 2, it is characterised in that the raw material presses following parts by weight
Proportioning：
Ginseng 170-210 Ganodenna Lucidum P.E 30-60 Herb Gynostemmae Pentaphylli extracts 30-60
Gadol extract 30-60 Schisandra chinens P.Es 20-50.
5. a kind of liver protecting health food according to claim 2, it is characterised in that the raw material presses following parts by weight
Proportioning：
The Herb Gynostemmae Pentaphylli extract 50 of 180 Ganodenna Lucidum P.E of ginseng 50
The Schisandra chinens P.E 30 of gadol extract 40.
6. a kind of liver protecting health food according to claim 2, it is characterised in that the food is capsule form.
7. a kind of a kind of preparation method of liver protecting health food as claimed in claim 2, comprises the following steps：
1. dispensing：Weight point weighs raw material, and ginseng crushed after being dried crosses 100 mesh sieves formation ginseng fine powder, and sterilizing is standby；By spirit
It is well mixed again with ginseng fine powder after sesame extract, Herb Gynostemmae Pentaphylli extract, gadol extract, Schisandra chinens P.E mixing；
2. pelletize：With 70-90% ethanol softwoods, above-mentioned dispensing into mixed material the granulation of 16 mesh is made, in 55-60 DEG C of drying,
Cross 14 mesh sieve whole grains；
3. fill：Particle after above-mentioned whole grain is loaded into No. 0 capsule, 18-25 DEG C of environment temperature, relative humidity 45%-60% is controlled；
4. polish：Populated capsule is put into capsule polisher, the dust in capsule surface is removed, surface smoothness is improved.
8. a kind of preparation method of liver protecting health food according to claim 7, it is characterised in that the dispensing step
In rapid, ginseng is in 50-70 DEG C of crushed after being dried；Ginseng fine powder 5kGy dosage60Co irradiation sterilizations.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610990989.4A CN107028164A (en) | 2016-11-11 | 2016-11-11 | A kind of liver protecting health food and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610990989.4A CN107028164A (en) | 2016-11-11 | 2016-11-11 | A kind of liver protecting health food and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107028164A true CN107028164A (en) | 2017-08-11 |
Family
ID=59531272
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610990989.4A Withdrawn CN107028164A (en) | 2016-11-11 | 2016-11-11 | A kind of liver protecting health food and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107028164A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108434274A (en) * | 2018-05-14 | 2018-08-24 | 蒋志秉 | A kind of Chinese medicine composition for protect liver |
| CN111714539A (en) * | 2019-03-22 | 2020-09-29 | 江苏康缘药业股份有限公司 | Liver-protecting composition and preparation method and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104042664A (en) * | 2014-06-14 | 2014-09-17 | 桓仁满族自治县益仁堂中药材有限公司 | Hypolipidemic granule |
-
2016
- 2016-11-11 CN CN201610990989.4A patent/CN107028164A/en not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104042664A (en) * | 2014-06-14 | 2014-09-17 | 桓仁满族自治县益仁堂中药材有限公司 | Hypolipidemic granule |
Non-Patent Citations (1)
| Title |
|---|
| 秦瑞东: "一种对化学性肝损伤有辅助保护作用的保健食品研发", 《中国优秀硕士学位论文全文数据库》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108434274A (en) * | 2018-05-14 | 2018-08-24 | 蒋志秉 | A kind of Chinese medicine composition for protect liver |
| CN108434274B (en) * | 2018-05-14 | 2021-01-08 | 蒋志秉 | Traditional Chinese medicine composition for protecting liver |
| CN111714539A (en) * | 2019-03-22 | 2020-09-29 | 江苏康缘药业股份有限公司 | Liver-protecting composition and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chen et al. | Effects of polysaccharide from Pueraria lobata on gut microbiota in mice | |
| JP6873517B2 (en) | Health-maintaining product composition applicable to adult women, the elderly and people in sub-health conditions | |
| US20080233220A1 (en) | Further Medical Use Of A Botanical Drug Or Dietary Supplement | |
| WO2015172608A1 (en) | Capsule for assisting in reducing blood fat and preparation method therefor | |
| CN102429949B (en) | Liver-protecting medicine or health care product composition and preparation method and application thereof | |
| CN101297704B (en) | Health care food for protecting liver and manufacturing method thereof | |
| Soldati | Panax ginseng: standardization and biological activity | |
| CN108472502A (en) | For treating liver and maintaining composition, method and the pharmaceutical composition of liver health | |
| WO2021213232A1 (en) | Application of traditional chinese medicine composition in preparing drug for treating or preventing hyperlipidemia | |
| CN107028164A (en) | A kind of liver protecting health food and preparation method thereof | |
| Li | Chinese herbal medicine | |
| CN105998652A (en) | Traditional Chinese medicine composition and application and preparation thereof | |
| CN107551001A (en) | A kind of Chinese herbal compounds and its preparation method for being used to prevent and treat alcoholic liver injury | |
| CN106579392A (en) | Composition for alleviating delayed onset muscle soreness | |
| CN103860706B (en) | A kind of pure Chinese medicine health preparation with protection alcoholic liver injury function | |
| CN106177172A (en) | A kind of for enhancing immunity, the Chinese medicine preparation and preparation method thereof of alleviating physical fatigue | |
| CN103599354B (en) | A kind of pine pollen composition and application thereof | |
| CN101342249A (en) | Chinese medicine formulations for treating hepatitis B and preparation method thereof | |
| CN108175801B (en) | Traditional Chinese medicine composition with chemical liver injury health care function and preparation method thereof | |
| CN104095912B (en) | Treat the preparation method of the Chinese patent drug of rheumatism bone disease | |
| CN109463758B (en) | A kind of anti-aging and the compound product and preparation method thereof for increasing moisture of skin | |
| CN103263458B (en) | Liver-protecting medicine or health-care product composition as well as preparation method and use thereof | |
| TW201821098A (en) | Black garlic extracts, preparing method thereof, and use thereof | |
| KR101985660B1 (en) | Cosmetic composition for treating acne containing mixed herbal extracts fermented with Nuruk | |
| Nasef | Study the effect of chicory (CichoriumIntybus, L.) leaves powder on some biochemical and biological parameters of hepatotoxicity induced by Ccl4 in rats |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170811 |